Cogent Biosciences financials
$31.66−0.63%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$102.6M | -$103.6M | -$99.5M | -$83.4M | -$75.6M | -$74.9M | -$73.7M | -$75.4M | -$64.4M | -$62.4M | -$58.2M | -$59.6M |
| Net income | -$88.9M | -$86.0M | -$88.4M | -$69.0M | -$60.9M | -$59.5M | -$55.6M | -$57.4M | -$42.9M | -$46.1M | -$16.9M | -$55.4M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.52 | $-0.53 | $-0.59 | $-0.50 | $-0.53 | $-0.52 | $-0.50 | $-0.52 | $-0.43 | $-0.49 | $-0.19 | $-0.64 |
| EBITDA | -$101.9M | -$103.0M | -$98.9M | -$82.7M | -$74.9M | -$74.3M | -$73.1M | -$74.8M | -$63.8M | -$61.8M | -$58.2M | -$59.0M |
| Operating cash flow | -$77.3M | -$86.9M | -$79.1M | -$64.3M | -$54.5M | -$66.5M | -$60.6M | -$52.0M | -$42.7M | -$52.5M | -$44.1M | -$38.0M |
| Free cash flow | -$77.6M | -$87.3M | -$79.9M | -$64.4M | -$54.7M | -$67.1M | -$60.7M | -$52.3M | -$42.8M | -$52.6M | -$44.4M | -$38.1M |
| Diluted shares | 171.0M | 162.2M | 150.3M | 137.6M | 114.5M | 113.3M | 111.2M | 110.2M | 99.2M | 94.8M | 87.0M | 86.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $181.2M | $241.2M | $312.0M | $125.3M | $127.6M | $126.0M |
| Short-term investments | $611.1M | $625.2M | $588.8M | $265.6M | $110.3M | $119.7M |
| Total debt | $223.5M | $223.2M | $222.9M | $44.3M | $43.9M | $0.00 |
| Total assets | $834.5M | $903.0M | $937.6M | $425.9M | $274.8M | $283.8M |
| Total liabilities | $302.2M | $295.3M | $301.2M | $123.5M | $119.8M | $64.8M |
| Shareholders' equity | $532.4M | $607.7M | $636.4M | $302.5M | $155.0M | $219.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology